Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: A pooled analysis of three studies conducted in North America and Europe

REFERENCES

• Warner Chilcott. Lo Loestrin Fe. Highlights of prescribing information. 2012. Accessed 28 January from: http://www.wcrx.com/pdfs/pi/pi_loloestrinfe.pdf.
   Google Scholar
• Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169–78.
   PubMed Web of Science ®Google Scholar
• Kiley J, Hammond C. Combined oral contraceptives: A comprehensive review. Clin Obstet Gynecol 2007;50: 868–77.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F. Beyaz®: An oral contraceptive fortified with folate. Womens Health (Lond Engl) 2012;8:13–9.
   PubMedGoogle Scholar
• Rapkin RB, Creinin MD. The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium. Expert Opin Pharmacother 2011;12:2403–10.
   PubMedGoogle Scholar
• Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception 2007;75:16–22.
   PubMed Web of Science ®Google Scholar
• Hoy SM, Scott LJ. Estradiol valerate/dienogest in oral contraception. Drugs 2009;69:1635–46.
   PubMed Web of Science ®Google Scholar
• Astedt B, Jeppsson S, Liedholm P, et al. Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17β-oestradiol. Br J Obstet Gynaecol 1979;86: 732–6.
   PubMedGoogle Scholar
• Kivinen S, Saure A. Efficacy and tolerability of a combined oral contraceptive containing 17β-estradiol and desogestrel. Eur J Contracept Reprod Health Care 1996;1:183.
   Google Scholar
• Koetsawang S, Mandlekar A, Krishna U, et al. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. Contraception 1980;21:445–59.
   PubMed Web of Science ®Google Scholar
• Schubert W, Cullberg G. Ovulation inhibition with 17β-estradiol cyclo-octyl acetate and desogestrel. Acta Obstet Gynecol Scand 1987;66:543–7.
   PubMed Web of Science ®Google Scholar
• Serup J, Bostofte E, Larsen S, et al. Natural oestrogens for oral contraception. Lancet 1979;2:471–2.
   PubMed Web of Science ®Google Scholar
• Wenzl R, Bennink HC, van Beek A, et al. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17β-estradiol. Fertil Steril 1993; 60:616–9.
   PubMed Web of Science ®Google Scholar
• Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577–82.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Parke S, Trummer D, et al. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: Results of two prospective, randomized, open-label studies. Contraception 2008;78:218–25.
   PubMed Web of Science ®Google Scholar
• Palacios S, Wildt L, Parke S, et al. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A Phase III trial. Eur J Obstet Gynecol Reprod Biol 2010;149:57–62.
   PubMed Web of Science ®Google Scholar
• Ahrendt HJ, Makalova D, Parke S, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: A seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 2009;80:436–44.
   PubMed Web of Science ®Google Scholar
• Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008;73: 222–31.
   PubMed Web of Science ®Google Scholar
• Oettel M, Breitbarth W, Elgar W, et al. The pharmacological profile of dienogest. Eur J Contracept Reprod Health Care 1999;4:2–13.
   Google Scholar
• Okada H, Nakajima T, Yoshimura T, et al. The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. Mol Hum Reprod 2001;7:341–7.
   PubMed Web of Science ®Google Scholar
• Guida M, Bifulco G, Di Spiezio Sardo A, et al. Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill. Int J Womens Health 2010;2:279–90.
   PubMedGoogle Scholar
• Mueck AO, Sitruk-Ware R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 2011; 76:531–9.
   PubMed Web of Science ®Google Scholar
• Belsey EM, Machin D, d’Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1986;34:253–60.
   PubMed Web of Science ®Google Scholar
• Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000;5:25–34.
   PubMedGoogle Scholar
• Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 2004;70:191–8.
   PubMed Web of Science ®Google Scholar
• Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006;73:229–34.
   PubMed Web of Science ®Google Scholar
• Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol 1993;100:832–8.
   PubMedGoogle Scholar
• Bayer HealthCare Pharmaceutical Inc. Natazia: Highlights of prescribing information. 2010. Accessed 19 June from: http://berlex.bayerhealthcare.com/html/products/pi/natazia_pi.pdf
   Google Scholar
• Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care 2011;16:430–43.
   PubMed Web of Science ®Google Scholar
• Westhoff C, Kaunitz A, Korver T, et al. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: A randomized controlled trial. Obstet Gynecol 2012;119: 989–99.
   PubMed Web of Science ®Google Scholar
• Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: A review of the literature. Eur J Contracept Reprod Health Care 2010;15:4–16.
   PubMed Web of Science ®Google Scholar
• Boerrigter PJ, Ellman H, Dolker M. International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 microg and ethinyl estradiol 20 microg. Clin Ther 1999;21: 118–27.
   PubMed Web of Science ®Google Scholar
• Hite RC, Bannemerschult R, Fox-Kuchenbecker P, et al. Large observational trial of a new low-dose oral contraceptive containing 20 micrograms ethinylestradiol and 100 micrograms levonorgestrel (Miranova) in Germany. Eur J Contracept Reprod Health Care 1999;4: 7–13.
   PubMedGoogle Scholar
• Archer DF, Maheux R, DelConte A, et al. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG). Contraception 1997;55:139–44.
   Google Scholar
• Endrikat J, Cronin M, Gerlinger C, et al. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. Contraception 2001;64:201–7.
   PubMed Web of Science ®Google Scholar